New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:59 EDTMGLN, NCI, DYAX, BCRX, VRTS, EPE, SBNYOn The Fly: Analyst Initiation Summary
Magellan Health (MGLN) initiated with a Market Perform at Leerink... Virtus Investment Partners (VRTS) initiated with a Neutral at BofA/Merrill... Signature Bank (SBNY) coverage resumed with a Buy at Goldman... Dyax (DYAX) initiated with an Outperform at Oppenheimer... BioCryst (BCRX) initiated with a Perform at Oppenheimer... Navigant Consulting (NCI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Equal Weight at Morgan Stanley.
News For MGLN;VRTS;DYAX;SBNY;BCRX;NCI;EPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
13:51 EDTBCRXPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
09:05 EDTVRTSVirtus Investment Partners 'disappointed' with elevated mutual fund redemptions
Subscribe for More Information
09:04 EDTVRTSVirtus Investment Partners reports Q4 EPS $2.05, consensus $2.42
Subscribe for More Information
January 26, 2015
16:05 EDTVRTSVirtus Investment Partners to acquire majority stake in ETF issuer solutions
Subscribe for More Information
09:56 EDTBCRXBioCryst management to meet with JPMorgan
Meetings to be held in Boston on January 29-30 hosted by JPMorgan.
09:19 EDTBCRXOn The Fly: Pre-market Movers
Subscribe for More Information
06:59 EDTBCRXBioCryst grants fast track designation for BCX4161
BioCryst announced that the FDA has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema. BioCryst is enrolling HAE patients in the OPuS-2 trial of BCX4161; a double-blind, randomized, placebo controlled trial conducted in the U.S. and certain EU countries, with the goal of demonstrating the efficacy and safety of BCX4161 treatment for 12 weeks in approximately 100 patients with HAE. BioCryst expects to report results from OPuS-2 by the end of 2015.
January 25, 2015
13:57 EDTBCRXUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 22, 2015
05:32 EDTSBNYSignature Bank reports Q4 EPS $1.60, consensus $1.56
Subscribe for More Information
January 19, 2015
11:21 EDTMGLNMagellan Health announces that NIA Magellan broadens capabilities
Magellan Health announced that NIA Magellan, which offers a suite of specialty solutions to address many complex areas of healthcare, plans to broaden its capabilities to include management of chiropractic care, physical therapy, occupational therapy and speech therapy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use